$IMA Cashflow Statement | Understand Stock

$IMA

$4.02 -$0.03 (0.74%) Close

$IMA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Depreciation and amortization
Non-cash interest expense
Stock-based compensation expense
Non-cash operating lease expense
Accretion/amortization of premium/discount of available-for-sale securities
Amortization of marketable securities
Amortization of right of use-assets
Gain on early extinguishment of lease liability
Loss on disposal of property and equipment
Impairment of right of use asset
Impairment of assets held for sale
Net realized loss on marketable securities
Non-cash research and development expenses for the common stock issuable pursuant to Hutchmed Agreement
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Deposits and other assets
Other non-current assets
Accounts payable
Accrued expenses and other current liabilities
Deferred revenue
Operating lease liabilities
Lease liability
Other long-term liabilities

Net cash used in operating activities
Cash flows from investing activities:
Purchases of property and equipment
Cash divested in Non-OX40 divestiture
Proceeds from disposal of property and equipment
Purchases of marketable securities
Maturities and sales of marketable securities
Amounts loaned under note receivable
Net cash (used in) provided by investing activities
Cash flows from financing activities:
Cash and cash equivalents acquired in connection with the acquisition of Pionyr, net of issuance costs paid
Cash consideration paid in connection with the acquisition of Pionyr
Proceeds from issuance of common stock for underwritten registered offering, net of offering costs
Repurchase of common stock
Proceeds from term loan
Proceeds from exercise of stock options
Proceeds from issuance of preferred stock, net of offering costs
Proceeds from initial public offering, net of offering costs
Issuance costs in connection with reverse recapitalization
Cash acquired in connection with reverse recapitalization
Proceeds from common stock issued in PIPE Financing, net of issuance costs
Net cash provided by financing activities

Net increase (decrease) in cash, cash equivalents and restricted cash
Effects of exchange rates on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Cash and cash equivalents
Restricted cash included in deposits and other assets
Restricted cash included in other assets
Supplemental disclosure of cash flow information:
Right-of-use asset recognized upon assumption of San Francisco, CA lease from Pionyr
Purchases of property and equipment in accounts payable and accrued expenses
Right-of-use assets and lease liabilities recognized upon lease inception
Cash paid for income taxes, net

Supplemental disclosure of non-cash investing and financing information:
Accretion of redeemable convertible preferred shares
Deferred offering costs in accrued expenses and other current liabilities
Exchange of preferred shares into common stock upon closing of reverse recapitalization
Forgiveness of term loan upon closing of reverse recapitalization
Reverse recapitalization issuance costs in accrued expenses
Issuance of promissory note in connection with divesture
Net assets derecognized in connection with Non-OX40 Divestiture
Unrealized gain on marketable securities
Right-of-use assets acquired by assuming operating lease liability

Comments